Johnson & Johnson (NYSE:JNJ) Shares Sold by IFG Advisory LLC

Posted by Defense World Staff on Apr 21st, 2023

IFG Advisory LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 19.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,749 shares of the company’s stock after selling 3,738 shares during the quarter. IFG Advisory LLC’s holdings in Johnson & Johnson were worth $2,782,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $35,000. Retirement Financial Solutions LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $40,000. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the third quarter worth $48,000. VitalStone Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC increased its position in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $163.58 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $426.01 billion, a PE ratio of 24.27, a price-to-earnings-growth ratio of 2.75 and a beta of 0.53. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The company has a 50 day moving average price of $157.48 and a two-hundred day moving average price of $166.96.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.67 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.91%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on JNJ shares. Atlantic Securities reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday. Raymond James cut their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, UBS Group started coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.